Literature DB >> 22201520

Economic and humanistic burden of external genital warts.

Adam J N Raymakers1, Mohsen Sadatsafavi, Fawziah Marra, Carlo A Marra.   

Abstract

External genital warts (EGW) are a sexually transmitted infection caused by various strains of human papillomavirus (HPV). Several studies have described the direct and indirect costs of EGW, while others have reported on the burden of EGW in terms of the impact on the quality of life (QOL) of patients. The arrival of a quadrivalent HPV vaccine that protects against both cervical cancer and EGW requires a proper understanding of the impact of vaccines on costs and QOL. Using pre-defined search terms and inclusion/exclusion criteria, we performed a systematic review of the economic and humanistic burden of EGW. The focus of our review was on literature describing the direct and indirect costs of EGW per episode of care (EoC) or per year, as well as the impact of EGW on disease-specific, generic, or preference-based QOL measures. We also reviewed the literature on the national economic burden of EGW from the perspectives of different countries. Other aspects of EGW management that can inform economic modelling studies, such as length of EoC, number of physician visits and indirect costs, were also explored. Our review sheds light on the high economic and humanistic burden of EGW and important differences in the costs between men and women, as well as the differences in health resource utilization and costs across countries. Our study also highlights the dearth of information on the impact of EGW on the QOL and productivity of patients.

Entities:  

Mesh:

Year:  2012        PMID: 22201520     DOI: 10.2165/11591170-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  65 in total

Review 1.  Modeling the impact of treatment options in genital warts: patient-applied versus physician-administered therapies.

Authors:  P C Langley; G A Richwald; M H Smith
Journal:  Clin Ther       Date:  1999-12       Impact factor: 3.393

Review 2.  Genital warts and their treatment.

Authors:  K R Beutner; D J Wiley; J M Douglas; S K Tyring; K Fife; K Trofatter; K M Stone
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

3.  Assessing incidence and economic burden of genital warts with data from a US commercially insured population.

Authors:  Tracey Hoy; Puneet K Singhal; Vincent J Willey; Ralph P Insinga
Journal:  Curr Med Res Opin       Date:  2009-10       Impact factor: 2.580

4.  The cost effectiveness of patient-applied versus provider-administered intervention strategies for the treatment of external genital warts.

Authors:  P C Langley; S K Tyring; M H Smith
Journal:  Am J Manag Care       Date:  1999-01       Impact factor: 2.229

Review 5.  The epidemiology of genital human papillomavirus infection.

Authors:  Helen Trottier; Eduardo L Franco
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

6.  The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.

Authors:  Marc Brisson; Nicolas Van de Velde; Philippe De Wals; Marie-Claude Boily
Journal:  Vaccine       Date:  2007-05-22       Impact factor: 3.641

7.  The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

Authors:  E J Dasbach; R P Insinga; E H Elbasha
Journal:  BJOG       Date:  2008-05-22       Impact factor: 6.531

8.  The psychosocial impact of human papillomavirus infection: implications for health care providers.

Authors:  P Clarke; C Ebel; D N Catotti; S Stewart
Journal:  Int J STD AIDS       Date:  1996 May-Jun       Impact factor: 1.359

9.  Cost-effectiveness of 21 alternative cervical cancer screening strategies.

Authors:  Anderson Chuck
Journal:  Value Health       Date:  2009-09-25       Impact factor: 5.725

10.  Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Authors:  Sue J Goldie; Meredith O'Shea; Nicole Gastineau Campos; Mireia Diaz; Steven Sweet; Sun-Young Kim
Journal:  Vaccine       Date:  2008-05-15       Impact factor: 3.641

View more
  12 in total

1.  The Economic Value of Vaccination: Why Prevention is Wealth.

Authors: 
Journal:  J Mark Access Health Policy       Date:  2015-08-12

2.  Medical Care Costs Associated with Genital Warts for Commercially Insured US Patients.

Authors:  Kristina R Dahlstrom; Shuangshuang Fu; Wenyaw Chan; Zeena Shelal; Lois M Ramondetta; David R Lairson
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

3.  Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.

Authors:  Rémi Marty; Stéphane Roze; Xavier Bresse; Nathalie Largeron; Jayne Smith-Palmer
Journal:  BMC Cancer       Date:  2013-01-08       Impact factor: 4.430

4.  Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.

Authors:  Ellinor Östensson; Maria Fröberg; Amy Leval; Ann-Cathrin Hellström; Magnus Bäcklund; Niklas Zethraeus; Sonia Andersson
Journal:  PLoS One       Date:  2015-09-23       Impact factor: 3.240

Review 5.  Systematic review of the incidence and prevalence of genital warts.

Authors:  Harshila Patel; Monika Wagner; Puneet Singhal; Smita Kothari
Journal:  BMC Infect Dis       Date:  2013-01-25       Impact factor: 3.090

6.  A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.

Authors:  Xavier Bresse; Marjorie Adam; Nathalie Largeron; Stephane Roze; Rémi Marty
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

7.  Role of vaccination in the sustainability of healthcare systems.

Authors:  Nathalie Largeron; Pierre Lévy; Jürgen Wasem; Xavier Bresse
Journal:  J Mark Access Health Policy       Date:  2015-08-12

8.  Multimodal Counseling Interventions: Effect on Human Papilloma Virus Vaccination Acceptance.

Authors:  Oroma Nwanodi; Helen Salisbury; Curtis Bay
Journal:  Healthcare (Basel)       Date:  2017-11-06

9.  A cross-sectional study estimating the burden of illness related to genital warts in South Korea.

Authors:  Taek Sang Lee; Smita Kothari-Talwar; Puneet K Singhal; Karen Yee; Amit Kulkarni; Nuria Lara; Montserrat Roset; Anna R Giuliano; Suzanne M Garland; Woong Ju
Journal:  BMJ Open       Date:  2017-07-02       Impact factor: 2.692

10.  Estimating the burden of illness related to genital warts in the Philippines: a nationally representative cross-sectional study.

Authors:  Lani Buenconsejo; Smita Kothari-Talwar; Karen Yee; Amit Kulkarni; Nuria Lara; Montserrat Roset; Anna R Giuliano; Suzanne Garland
Journal:  Infect Agent Cancer       Date:  2019-10-07       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.